AMGEN INC — Director's Dealing 2023

Sep 15, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Neumora Therapeutics, Inc. (NMRA)
CIK: 0001885522
Period of Report: 2023-09-14

Reporting Person: AMGEN INC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-2 Preferred Stock	$		Common Stock (32754291)		Direct
Series B Preferred Stock	$		Common Stock (849657)		Direct

Footnotes

F1: The shares of Series A-2 Preferred Stock of the Issuer will automatically convert on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.

F2: Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.

F3: The shares of Series B Preferred Stock of the Issuer will automatically convert on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.